Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document remibrutinib - BTK inhibitor Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic Immunology > Neuroscience Oncology Other Global Health Abbreviations References remibrutinib - BTK inhibitor NCT05147220 REMODEL-1 (CLOU064C12301) Multiple sclerosis Indication Phase Phase 3 Patients 800 Primary Outcome Measures Arms Intervention Target Patients Annualized relapse rate (ARR) of confirmed relapses [Core Part]. ARR is the average number of confirmed MS relapses in a year Arm 1: Experimental; Remibrutinib - Core (Remibrutinib tablet and matching placebo of teriflunomide capsule) Arm 2: Active Comparator; Teriflunomide - Core (Teriflunomide capsule and matching placebo remibrutinib tablet) Arm 3: Experimental; Remibrutinib - Extension (Participants on remibrutinib in Core will continue on remibrutinib tablet) Arm 4: Experimental; Remibrutinib - Extension (on teriflunomide in Core) (Participants on teriflunomide in Core will switch to remibrutinib tablet) Patients with relapsing Multiple Sclerosis Estimated primary completion 2026 Readout Milestone(s) Publication TBD NCT05156281 REMODEL-2 (CLOU064C12302) Indication Multiple sclerosis Phase Phase 3 Patients 800 Primary Outcome Measures Arms Intervention Annualized relapse rate (ARR) of confirmed relapses Target Patients Readout Milestone(s) Publication Arm 1: Experimental; Remibrutinib - Core Remibrutinib tablet and matching placebo of teriflunomide capsule Arm 2: Active Comparator; Teriflunomide - Core Teriflunomide capsule and matching placebo remibrutinib tablet Arm 3: Experimental: Remibrutinib - Extension Participants on remibrutinib in Core will continue on remibrutinib tablet Arm 4: Experimental: Remibrutinib - Extension (on teriflunomide in Core) Participants on teriflunomide in Core will switch to remibrutinib tablet Patients with relapsing Multiple Sclerosis Estimated primary completion 2026 TBD □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 67

View entire presentation